1. Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction.
- Author
-
Jacobsen, Mia Ravn, Engstrøm, Thomas, Torp-Pedersen, Christian, Gislason, Gunnar, Glinge, Charlotte, Butt, Jawad Haider, Fosbøl, Emil Loldrup, Holmvang, Lene, Pedersen, Frants, Køber, Lars, Jabbari, Reza, and Sørensen, Rikke
- Subjects
- *
ST elevation myocardial infarction , *PRASUGREL , *TICAGRELOR , *CLOPIDOGREL , *ISCHEMIC stroke - Abstract
To compare effectiveness and safety of clopidogrel, prasugrel, and ticagrelor among all-comers with ST-segment elevation myocardial infarction (STEMI) and extend the knowledge from randomized clinical trials. All consecutive patients with STEMI admitted to Copenhagen University Hospital, Rigshospitalet, from 2009 to 2016 were identified via the Eastern Danish Heart Registry. By individual linkage to Danish nationwide registries, claimed drugs and end points were obtained. Patients alive a week post-discharge were included, stratified according to clopidogrel, prasugrel, or ticagrelor treatment, and followed for a year. The effectiveness end point (a composite of all-cause mortality, recurrent myocardial infarction, and ischemic stroke) and safety end point (a composite of bleedings leading to hospitalization) were assessed by multivariate Cox proportional-hazards models. In total, 5123 patients were included (clopidogrel [1245], prasugrel [1902], ticagrelor [1976]) with ≥95% treatment persistency. Concomitant use of aspirin was ≥95%. Females accounted for 24% and elderly for 17%. Compared with clopidogrel, the effectiveness end point occurred less often for ticagrelor (HR 0.50, 95% CI 0.35–0.70) and prasugrel (HR 0.48, 95% CI 0.33–0.68) without differences in bleedings leading to hospitalization. No differences in comparative effectiveness or safety were found between prasugrel and ticagrelor. Sensitivity analyses with time-dependent drug exposure and the period 2011–2015 showed similar results. Among all-comers with STEMI, ticagrelor and prasugrel were associated with reduced incidence of the composite end point of all-cause mortality, recurrent myocardial infarction, and ischemic stroke without an increase in bleedings leading to hospitalization compared with clopidogrel. No differences were found between prasugrel and ticagrelor. • Prasugrel and ticagrelor were associated with superior effectiveness compared with clopidogrel in all-comers with STEMI • No increase in bleedings leading to hospitalization were demonstrated for prasugrel and ticagrelor compared with clopidogrel • No differences in comparative effectiveness or safety were found between ticagrelor and prasugrel • This study questions the merits of prasugrel over ticagrelor in all-comers with STEMI despite its observational design [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF